SCOR Valuation
Is SCRP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SCRP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SCRP (€23.8) is trading below our estimate of fair value (€72.37)
Significantly Below Fair Value: SCRP is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SCRP?
Key metric: As SCRP is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
What is SCRP's PS Ratio? | |
---|---|
PS Ratio | 0.3x |
Sales | €15.62b |
Market Cap | €4.32b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 0.5x |
Enterprise Value/EBITDA | 17.8x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does SCRP's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 0.8x | ||
CRE Conduit Holdings | 1.4x | 14.4% | UK£752.7m |
HSX Hiscox | 1.2x | 11.4% | UK£3.5b |
PHNX Phoenix Group Holdings | 0.2x | -27.6% | UK£5.0b |
DLG Direct Line Insurance Group | 0.6x | 0.7% | UK£2.0b |
SCRP SCOR | 0.3x | 9.5% | €4.3b |
Price-To-Sales vs Peers: SCRP is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (0.8x).
Price to Sales Ratio vs Industry
How does SCRP's PS Ratio compare vs other companies in the GB Insurance Industry?
1 Company | Price / Sales | Estimated Growth | Market Cap |
---|---|---|---|
RQIH R&Q Insurance Holdings | 0.001x | n/a | US$360.20k |
1 Company | Estimated Growth | Market Cap |
---|
Price-To-Sales vs Industry: SCRP is good value based on its Price-To-Sales Ratio (0.3x) compared to the European Insurance industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is SCRP's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 0.3x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate SCRP's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | €23.80 | €25.99 +9.2% | 16.6% | €36.00 | €19.00 | n/a | 15 |
Nov ’25 | €19.85 | €25.59 +28.9% | 21.7% | €37.00 | €18.00 | n/a | 15 |
Oct ’25 | €19.75 | €25.65 +29.9% | 22.1% | €37.00 | €18.00 | n/a | 15 |
Sep ’25 | €19.22 | €26.05 +35.6% | 22.4% | €37.00 | €18.00 | n/a | 15 |
Aug ’25 | €19.08 | €27.89 +46.2% | 19.3% | €37.00 | €19.00 | n/a | 15 |
Jul ’25 | n/a | €33.75 0% | 9.3% | €39.00 | €27.00 | n/a | 15 |
Jun ’25 | €26.38 | €33.96 +28.7% | 8.1% | €39.00 | €28.00 | n/a | 15 |
May ’25 | n/a | €34.79 0% | 9.2% | €40.00 | €28.00 | n/a | 15 |
Apr ’25 | n/a | €34.47 0% | 9.5% | €40.00 | €28.00 | n/a | 15 |
Mar ’25 | n/a | €32.99 0% | 7.0% | €37.00 | €27.00 | n/a | 16 |
Feb ’25 | n/a | €32.96 0% | 7.1% | €37.00 | €27.00 | n/a | 16 |
Jan ’25 | n/a | €32.91 0% | 8.1% | €37.00 | €27.00 | n/a | 16 |
Dec ’24 | n/a | €32.91 0% | 8.1% | €37.00 | €27.00 | n/a | 16 |
Nov ’24 | €27.69 | €31.97 +15.5% | 12.9% | €37.00 | €23.50 | €19.85 | 16 |
Oct ’24 | €30.01 | €31.28 +4.3% | 11.9% | €36.40 | €23.50 | €19.75 | 16 |
Sep ’24 | n/a | €30.68 0% | 11.4% | €36.00 | €23.50 | €19.22 | 16 |
Aug ’24 | €27.09 | €30.68 +13.3% | 11.4% | €36.00 | €23.50 | €19.08 | 16 |
Jul ’24 | €26.93 | €27.87 +3.5% | 14.9% | €35.00 | €20.00 | n/a | 17 |
Jun ’24 | €24.51 | €27.75 +13.2% | 14.5% | €34.00 | €20.00 | €26.38 | 17 |
May ’24 | n/a | €26.63 0% | 11.9% | €32.00 | €20.00 | n/a | 17 |
Apr ’24 | €20.86 | €26.69 +27.9% | 12.1% | €32.00 | €20.00 | n/a | 17 |
Mar ’24 | €23.16 | €25.68 +10.9% | 16.0% | €32.00 | €17.50 | n/a | 16 |
Feb ’24 | €22.52 | €25.43 +12.9% | 15.9% | €32.00 | €17.50 | n/a | 16 |
Jan ’24 | €22.19 | €23.76 +7.1% | 17.7% | €30.00 | €16.50 | n/a | 16 |
Dec ’23 | €18.80 | €23.73 +26.2% | 17.8% | €30.00 | €16.50 | n/a | 16 |
Nov ’23 | €14.46 | €23.60 +63.3% | 18.5% | €30.00 | €16.00 | €27.69 | 16 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Hiscox
UK£3.5b
Through its subsidiaries, provides insurance and reinsurance services in the United Kingdom, Europe, the United States, and internationally.
HSX
UK£10.36
7D
-2.3%
1Y
3.1%
Münchener Rückversicherungs-Gesellschaft in München
€62.6b
Engages in the insurance and reinsurance businesses worldwide.
0KFE
€472.30
7D
-1.5%
1Y
24.0%
Powszechny Zaklad Ubezpieczen
zł35.5b
Provides life and non-life insurance products and services in Poland, the Baltic States, and Ukraine.
0MYY
zł41.01
7D
-0.3%
1Y
n/a